China Development Co., Ltd. (600538.SH): Vigorously expand the field of general health and judicial IVD
Gelonghui, May 15, 丨 Guofa Co., Ltd. (600538.SH) said at the performance briefing that the stock price is affected by multiple factors such as macroeconomics, industry policies, and market environment. The company's management closely monitors the company's stock price fluctuations and attaches great importance to market value management. The company will focus on its main business, continue to do a good job in business management, consolidate the foundation for development, and continuously enhance the company's internal value. At the same time, we will continue to focus on the company's long-term development goals, innovative ideas, and focus on health development strategies, take high-tech development as the lead, use existing industries as the foundation, biotechnology as the core, and vigorously expand the field of health and judicial IVD, especially the roots
China Fa Co., Ltd. (600538.SH) announced first-quarter results with a net loss of 12.358 million yuan
Guofa Co., Ltd. (600538.SH) released its report for the first quarter of 2024, achieving operating income of 875 during the reporting period...
China Fa Co., Ltd. (600538.SH) announced 2023 annual results with a net loss of 82.3083 million yuan, which changed year-on-year from profit to loss
Guofa Co., Ltd. (600538.SH) disclosed its 2023 annual report. The company achieved operating income of 3 during the reporting period...
There's Reason For Concern Over Beihai Gofar Chuanshan Biological Co., Ltd.'s (SHSE:600538) Massive 26% Price Jump
Beihai Gofar Chuanshan Biological Co., Ltd. (SHSE:600538) shares have had a really impressive month, gaining 26% after a shaky period beforehand. Notwithstanding the latest gain, the annual share p
China Development Co., Ltd. (600538.SH): Part of the company's shares held by the controlling shareholder will be auctioned by the court
On March 11, Ge Longhui Co., Ltd. (600538.SH) announced that the controlling shareholder Zhu Ronghuan has 11.5 million unrestricted tradable shares of Beihai Guofa Chuanshan Biology Co., Ltd. (2.19% of the company's total share capital) will be judicially auctioned by the People's Court of Tianqiao District, Jinan City, Shandong Province on April 8, 2024.
Guofa Co., Ltd. (600538.SH): Sun Company Goldman Sachs Intelligent Manufacturing obtained a high-tech enterprise certificate
Gelonghui Co., Ltd. (600538.SH) announced that Guangzhou Goldman Sachs Intelligent Manufacturing Technology Co., Ltd., a wholly-owned subsidiary holding 52% of Guangzhou Goldman Sachs Biotechnology Co., Ltd., recently received the “High-tech Enterprise Certificate” jointly issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the Guangdong Provincial Taxation Bureau of the State Administration of Taxation. This is a re-certification carried out after the expiration of the original Goldman Sachs Intelligent Manufacturing High-tech Enterprise Certificate.
China Fa Co., Ltd. (600538.SH): Expected net loss of around 82 million yuan in 2023
Gelonghui, January 26丨Guofa Co., Ltd. (600538.SH) announced that according to preliminary estimates by the finance department, net profit attributable to owners of the parent company is expected to be around -82 million yuan in 2023, which is a loss compared with the same period last year (legally disclosed data). Net profit attributable to the owner of the parent company after deducting non-recurring profit and loss is expected to be around -84 million yuan in 2023. Guangzhou Goldman Sachs Biotechnology Co., Ltd., a wholly-owned subsidiary, was affected by factors such as falling customer demand and fewer winning projects. The amount of contracts that can be executed throughout the year decreased year-on-year, revenue declined, and gross profit declined
Guofa Co., Ltd. (600538.SH): Sun's subsidiary was recognized as a specialized, special and new enterprise in Guangdong Province
Gelonghui, January 9 | Guofa Co., Ltd. (600538.SH) announced that according to the “Notice on Announcing the 2023 Specialized and New Small and Medium Enterprises and the List of Companies Passing the 2020 Expiry Review (Notice [2024] No. 1)” recently issued by the Guangdong Provincial Department of Industry and Information Technology, Guangzhou Goldman Sachs Intelligent Manufacturing Technology Co., Ltd., a wholly-owned subsidiary of the company, Guangzhou Goldman Sachs Intelligent Manufacturing Technology Co., Ltd., which holds 52% of the shares, was recognized as a 2023 specialized and innovative SME, which is valid for three years, that is, from January 6, 2024 to January 5, 2027.
Wu Peicheng, director of China Development Co., Ltd. (600538.SH), completed a reduction of 701,300 shares
Guofa Co., Ltd. (600538.SH) announced that company director Wu Peicheng reduced his holdings of the company's shares by 701,300, accounting for the total...
Guofa Co., Ltd. (600538.SH) released its results for the first three quarters, with a net loss of 15.73 million yuan
China Development Co., Ltd. (600538.SH) disclosed its third report for 2023. The company achieved revenue of 2.8 in the first three quarters...
Guofa Co., Ltd. (600538.SH): Currently, pharmaceutical companies' sales channels are mainly offline channels, and online channels are parallel
GLONGHUI, September 22 | Guofa Co., Ltd. (600538.SH) said at the semi-annual performance briefing that Guofa Chuanshan Biopharmaceutical Factory has a series of products from the three major brands of Haibao, Haima, and Guofa. The Haibao Pearl Eye Drops it produces are a well-known ophthalmology medicine in China. Specialty marine biopharmaceuticals such as Haibao Pearl Powder and Haibao Pearl Layer Powder are selected and have good curative effects, and are favored by domestic and foreign consumers. Beihai Guofa Chuanshan Pharmaceutical has implemented a more in-depth and multi-dimensional marketing strategy in terms of brand building, and is continuously increasing brand promotion efforts around new media. Currently, pharmaceutical companies' sales channels are mainly offline channels,
China Development Co., Ltd. (600538.SH): Net loss of 9.75 million yuan in the first half of the year was converted to loss year-on-year
GLONGHUI, August 25 | Guofa Co., Ltd. (600538.SH) announced its semi-annual report. Operating income was 194 million yuan, down 11.41% year on year, net loss of 9.75 million yuan, year-on-year loss of 9.75 million yuan, net loss of 10.5379 million yuan, net loss of 10.5379 million yuan, converted to losses year over year, and basic earnings per share of -0.02 yuan.
China Development Co., Ltd. (600538.SH): Net profit advance loss of about 9 million yuan for the half year
On July 15, | GLONGHUI Co., Ltd. (600538.SH) announced the advance loss announcement for the 2023 semi-annual results. According to preliminary estimates by the finance department, it is estimated that net profit attributable to owners of the parent company in the half year 2023 will be around -9 million yuan. Compared with the same period last year, there will be losses. Net profit after deducting non-recurring profit and loss attributable to owners of the parent company is expected to be around -9.5 million yuan in the half year of 2023. Guangzhou Goldman Sachs Biotechnology Co., Ltd., a wholly-owned subsidiary, had a year-on-year decrease in the amount of contracts that could be executed in the first half of the year due to fewer winning projects, lower revenue, and a year-on-year margin rate
China Development Co., Ltd. (600538.SH) is forecasting a loss. It expects a net loss of about 9 million yuan for the half year, changing from profit to loss over the previous year
According to the Zhitong Finance App, China Development Co., Ltd. (600538.SH) issued an advance loss announcement for the 2023 semi-annual results. It is estimated that net profit attributable to the owners of the parent company will be around -9 million yuan for the half year 2023. Compared with the same period last year, there will be losses. Net profit after deducting non-recurring profit and loss attributable to owners of the parent company is expected to be around -9.5 million yuan in the half year of 2023. Guangzhou Goldman Sachs Biotechnology Co., Ltd., a wholly-owned subsidiary, had a year-on-year decrease in the amount of enforceable contracts in the first half of the year, a year-on-year decrease in revenue, and a year-on-year decline in gross margin due to fewer projects winning bids, resulting in a year-on-year ratio of its profits
Earnings growth of 1.6% over 5 years hasn't been enough to translate into positive returns for Beihai Gofar Chuanshan Biological (SHSE:600538) shareholders
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But every investor is virtually certain to have both over-performing
Guofa shares: received 1 million yuan in incentive funds for mergers and acquisitions
Guofa shares (600538) announced that, according to the relevant regulations jointly issued by the Local Financial Supervision Bureau of Guangxi Zhuang Autonomous region and the Department of Finance of Guangxi Zhuang Autonomous region on the issuance of rules for the implementation of direct financing incentive policies for Guangxi to build a financial open door to ASEAN, on December 30, 2021, the company received 1 million yuan in incentive funds for mergers and acquisitions allocated by Beihai City Financial work Office.
Guofa shares (600538.SH): the interests held by Zhu Rongjuan and Yao Fangyuan decreased by 5%.
Guofa shares (600538.SH) announced that from January 4, 2021 to December 23, 2021, the company's controlling shareholder Zhu Rongjuan and her concerted actor Yao Fangyuan reduced their holdings in the company by a total of 22.745 million shares through centralized bidding transactions and block transactions, with a total reduction ratio of 4.38%. On July 28, 2021, the company issued shares in private. Since the disclosure obligors (Zhu Rongjuan and Yao Fangyuan) did not participate in the subscription of the non-public offering, the total proportion of shares held by Zhu Rongjuan and Yao Fangyuan after the non-public offering was
The controlling shareholder of Guofa (600538.SH) and its actors together reduced their shares by 4.38%.
Zhitong Financial App News, Guofa shares (600538.SH) issued an announcement that from January 4, 2021 to December 23, 2021, the company's controlling shareholder Zhu Rongjuan and her concerted actor Yao Fangyuan reduced their holdings in the company by a total of 22.745 million shares, a total of 4.38%.
The latest announcement of Guofa shares: 19.3334 million restricted shares will be lifted from listing on December 30th.
Guofa shares announced the non-public offering restricted shares part of the listing and circulation announcement, the number of restricted shares listed in circulation is 19.3334 million shares, the listing date of the restricted shares is December 30, 2021. The chairman of the company is Pan Libin. Mr. Pan Libin: he was born in May 1964 with a doctorate degree. After graduating from university in 1987, he stayed in Nanfang Hospital affiliated to Southern Medical University (former first military Medical University) to work in medicine, teaching and research. Later, he held an important position in Sanjiu (999) Group. He was in charge of the external medical management consulting project on behalf of BIMBA of the National Institute of Development of Peking University, and once served as the third member of Guangdong Province.
Guofa shares (600538.SH): the controlling shareholders have reduced their holdings by 1.18% recently.
Guofa shares (600538.SH) announced on December 24th that the company recently received a "notification letter on the reduction of more than 1% of the company's shares" by Zhu Rongjuan, the controlling shareholder. Zhu Rongjuan recently reduced her holdings of 6.175 million shares of the company through block transactions and centralized bidding transactions, accounting for 1.18% of the company's total share capital. After this change of rights and interests, the proportion of shares held by Zhu Rongjuan in the company decreased from 20.05% to 18.87%.
No Data